🇺🇸 FDA

Intelligence · Clinical Pipeline

Phase II Pipeline Programs

Proof-of-concept and dose-finding clinical programs in Phase II development.

Programs
7,238

Quick answer

NovaPharmaNews tracks 7,238 phase ii pharmaceutical pipeline programs from ClinicalTrials.gov. Proof-of-concept and dose-finding clinical programs in Phase II development.

Top sponsors

Page 13 of 151

  1. AZD5069

    United Therapeutics Europe Ltd

    Metastatic Castration Resistant Prostate Cancer

    phase 2 small molecule terminated

    1 trial

  2. AZD5363

    Cardiff Oncology

    Estrogen Receptor Positive Breast Cancer

    phase 2 small molecule active

    1 trial

  3. AZD5363

    United Therapeutics Europe Ltd

    Adenocarcinoma of the Prostate

    phase 2 small molecule active

    1 trial

  4. AZD5363 when combined with weekly paclitaxel.

    AstraZeneca

    Advanced or Metastatic Breast Cancer

    phase 2 small molecule completed

    1 trial

  5. AZD5462, AZD5462, The AZD5462 film-coated tablet placebo contains microcrystalline cellulose, magnesium stearate, polyvinyl alcohol, titanium dioxide, macrogol (polyethylene glycol) and talc. It is supplied in the same pack as the active and should be stored according to instructions on the label., AZD5462

    AstraZeneca AB

    Chronic Heart Failure

    phase 2 small molecule active

    1 trial

  6. AZD6738

    United Therapeutics Europe Ltd

    Breast Neoplasm

    phase 2 small molecule active

    1 trial

  7. AZD6738, Ceralasertib

    AstraZeneca AB

    Advanced Cancer Whose Tumours Contain Molecular Alterations

    phase 2 small molecule active

    1 trial

  8. AZD6738, Lynparza 100 mg film-coated tablets, Lynparza 150 mg film-coated tablets, Ceralasertib, AZD6738

    AstraZeneca AB

    Triple Negative Breast Cancer

    phase 2 small molecule active

    1 trial

  9. AZD6793

    AstraZeneca

    Chronic Obstructive Pulmonary Disease (COPD)

    phase 2 small molecule active

    1 trial

  10. AZD6793, AZD6793 Placebo, AZD6793, AZD6793

    AstraZeneca AB

    Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

    phase 2 small molecule active

    1 trial

  11. AZD7789

    AstraZeneca AB

    Advanced or metastatic gastric and gastro-esophageal junction (GEJ) adenocarcinoma, Advanced or Metastatic Non-small Cell Lung Carcinoma, Advanced or Metastatic Solid Tumors

    phase 2 small molecule active

    1 trial

  12. AZD7798 Placebo, AZD7798

    AstraZeneca AB

    Crohn's Disease

    phase 2 small molecule active

    1 trial

  13. AZD7798 Placebo: 0.9% saline solution for injection, commercially available., AZD7798

    AstraZeneca AB

    Crohn’s Disease and an Ileostomy

    phase 2 small molecule active

    1 trial

  14. AZD8630, AZD8630, AZD8630 Placebo, AZD8630

    AstraZeneca AB

    Asthma in adults who remain uncontrolled despite medium to high dose ICS plus LABA, and who are at risk of exacerbations.

    phase 2 small molecule active

    1 trial

  15. AZD8931

    United Therapeutics Europe Ltd

    Metastatic Colorectal Cancer

    phase 2 small molecule completed

    1 trial

  16. AZD8931

    AstraZeneca

    Neoplasms

    phase 2 small molecule terminated

    1 trial

  17. AZD9291

    Hospital Authority, Hong Kong

    Carcinoma, Non-Small-Cell Lung

    phase 2 small molecule active

    1 trial

  18. AZD9291

    Samsung Bioepis NL B.V.

    Non-Small Cell Lung Cancer With EGFR T790M Mutation

    phase 2 small molecule active

    1 trial

  19. AZD9574, DS-8201a, TEMOZO-cell ®250 mg Hartkapseln, AZD9574, TEMOZO-cell® 140 mg Hartkapseln, TEMOZO-cell® 100 mg Hartkapseln, TEMOZO-cell® 20 mg Hartkapseln, AZD9574, TEMOZO-cell® 180 mg Hartkapseln, TEMOZO-cell® 5 mg Hartkapseln, AZD9574, Datopotamab deruxtecan

    AstraZeneca AB

    Module 1: advanced/relapsed ovarian, breast, pancreatic or prostate cancer where patients loss of function or predicted loss of function mutation in BRCA1, BRCA2, PALB2, RAD51C, or RAD51D, Module 4: advanced,unresectable and HER2+ metastatic solid tumours; NSCLC, HER2 activating mutation, Module 5: advanced,unresectable or metastatic solid tumours in breast, endometrial, ovarian and prostate cancer, Module 3: advanced/relapsed HER2-negative breast, ovarian, prostate, or pancreatic cancer and expressing BRCA1m, BRCA2m, PALB2m, RAD51Cm or RAD51Dm, IDH-mutant recurrent glioma, breast cancer (without BM), Module 2: IDH-mutant glioma

    phase 2 small molecule active

    1 trial

  20. AZD9668

    AstraZeneca

    Chronic Obstructive Pulmonary Disease

    phase 2 small molecule completed

    1 trial

  21. AZD9750, Saruparib

    AstraZeneca AB

    Metastatic Prostate Cancer

    phase 2 small molecule active

    1 trial

  22. AZD9793

    AstraZeneca AB

    Hepatocellular Carcinoma

    phase 2 small molecule active

    1 trial

  23. AZITROMICINA ZENTIVA 500 mg compresse rivestite con film, Bassado 100 mg compresse, CEBION

    Sana Biotechnology

    Breast Cancer

    phase 2 small molecule active

    1 trial

  24. Abatacept

    Ultragenyx UK Limited

    Takayasu's Arteritis

    phase 2 small molecule completed

    1 trial

  25. Abatacept

    Ultragenyx UK Limited

    Wegener's Granulomatosis

    phase 2 small molecule completed

    1 trial

  26. Abatacept s.c.

    The First People's Hospital of Lianyungang

    Abatacept

    phase 2 small molecule active

    1 trial

  27. Abemaciclib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Liver Metastases From Colorectal Cancer (mCRC)

    phase 2 small molecule active

    1 trial

  28. Abemaciclib

    KAZIA THERAPEUTICS LTD

    CDK Gene Mutation

    phase 2 small molecule active

    1 trial

  29. Abemaciclib

    Teva Pharma GmbH

    Triple Negative Breast Neoplasms

    phase 2 small molecule active

    1 trial

  30. Abemaciclib, Abemaciclib, Verzenios 50 mg film-coated tablets, TEMOZOLOMIDE

    Eli Lilly Co.

    Glioma

    phase 2 small molecule active

    1 trial

  31. Abemaciclib, TEMOZOLOMIDE , Verzenios 50 mg film-coated tablets, IRINOTECAN

    Eli Lilly Co.

    Relapsed/Refractory Solid Tumors

    phase 2 small molecule active

    1 trial

  32. Abemaciclib, dexamethasone, ixazomib, pomalidomide

    Karyopharm Therapeutics Inc

    Relapsed Refractory Multiple Myeloma

    phase 2 small molecule completed

    1 trial

  33. Abevmy 25 mg/mL concentrate for solution for infusion., CAPECITABINE VIATRIS 150 mg, comprimé pelliculé, IRINOTECAN VIATRIS 20 mg/ml, solution à diluer pour perfusion, OXALIPLATINE ARROW LAB 5 mg/mL, solution à diluer pour perfusion, Fluorouracil 25 mg/ml Solution for Injection or Infusion, Erbitux 5 mg/mL solution for infusion, Vectibix 20 mg/ml concentrate for solution for infusion

    CERO THERAPEUTICS HOLDINGS, INC.

    Patients with newly diagnosed advanced peritoneal metastasis from colon and colorectal junction cancer

    phase 2 small molecule active

    1 trial

  34. Abexinostat

    Xynomic Pharmaceuticals

    Non Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  35. Abiprubart

    Kiniksa Pharmaceuticals International, plc

    Sjögrens Disease

    phase 2 small molecule terminated

    1 trial

  36. Abiraterone Acetate

    United Therapeutics Europe Ltd

    Metastatic Castration Resistant Prostate Cancer

    phase 2 small molecule terminated

    1 trial

  37. Abiraterone Acetate

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Prostate Cancer

    phase 2 small molecule active

    1 trial

  38. Abiraterone acetate

    United Therapeutics Europe Ltd

    Prostate Cancer (Adenocarcinoma)

    phase 2 small molecule active

    1 trial

  39. Abraxane

    Duke University

    Metastatic Breast Cancer

    phase 2 small molecule terminated

    1 trial

  40. Abraxane 5 mg/ml powder for dispersion for infusion., CISPLATIN, VALPROIC ACID, SIMVASTATIN, CAPECITABINE, VALPROIC ACID, GEMCITABINE

    Fondazione Telethon ETS

    Metastatic pancreatic ductal adenocarcinoma (mPDAC)

    phase 2 small molecule active

    1 trial

  41. Abraxane 5 mg/ml powder for dispersion for infusion., Gemcitabin-GRY 1000 mg Pulver zur Herstellung einer Infusionslösung, RoActemra 20 mg/mL concentrate for solution for infusion, Gemcitabin AqVida 38 mg/ml Pulver zur Herstellung einer Infusionslösung, Gemcitabin Kabi 38 mg/ml Pulver zur Herstellung einer Infusionslösung, Avastin 25 mg/ml concentrate for solution for infusion., ATEZOLIZUMAB, Tiragolumab

    Hoffmann-La Roche

    Pancreatic ductal adenocarcinoma (PDAC)

    phase 2 small molecule active

    1 trial

  42. Abraxane 5 mg/ml powder for dispersion for infusion., IRINOTECAN VIATRIS 20 mg/ml, solution à diluer pour perfusion, FLUOROURACILE ACCORD 50 mg/ml, solution à diluer pour perfusion, Gemcitabine Accord 100 mg/ml koncentratas infuziniam tirpalui, OXALIPLATINE ARROW LAB 5 mg/mL, solution à diluer pour perfusion, FLUOROURACILE ACCORD 50 mg/ml, solution à diluer pour perfusion, LEVOFOLINATE DE CALCIUM ZENTIVA 25 mg/2,5ml, solution injectable (IM/IV)

    The George Institute

    local advenced pancreatic adenocarcinoma

    phase 2 small molecule active

    1 trial

  43. Abraxane 5 mg/ml powder for dispersion for infusion., PEMETREXED , GEN1042 DP, CARBOPLATIN , FLUOROURACIL , PACLITAXEL , PEMBROLIZUMAB, GEMCITABINE , CISPLATIN

    Genmab A/S

    Malignant solid tumors: Patients with relapsed or refractory, advanced and/or metastatic melanoma, Non-Small Cell Lung Cancer (NSCLC), Head and neck squamous cell carcinoma (HNSCC), Panctreatic ductal adenocarcinoma (PDAC) or Colorectal Cancer (CRC).

    phase 2 small molecule active

    1 trial

  44. Abraxane, CAAA614A12101, PACLITAXEL ALBUMIN-BOUND, OXALIPLATIN, FLUOROURACIL, AAA614, IRINOTECAN, AAA514, CALCIUM FOLINATE

    Novartis Pharmaceuticals

    Recurrent or metastatic non-small cell lung cancer (NSCLC), Locally advanced unresectable or metastatic pancreatic ductal adenocarcinoma (PDAC), Metastatic Breast Carcinoma (BC)

    phase 2 small molecule active

    1 trial

  45. Absorbable and moldable skull base support plate

    The First People's Hospital of Lianyungang

    Sellar Tumor

    phase 2 other active

    1 trial

  46. Acalabrutinib

    TG THERAPEUTICS, INC.

    Chronic Lymphocytic Leukemia

    phase 2 small molecule active

    1 trial

  47. Acalabrutinib

    United Therapeutics Europe Ltd

    Mantle Cell Lymphoma

    phase 2 small molecule active

    1 trial

  48. Acasunlimab, Abraxane 5 mg/ml powder for dispersion for infusion., KEYTRUDA 25 mg/mL concentrate for solution for infusion, Pemetrexed Accord 100 mg powder for concentrate for solution for infusion., Cisplatin 1mg/ml Injection BP, Carboplatin 10 mg/ml Intravenous Infusion, Pazenir 5 mg/ml powder for dispersion for infusion., Abraxane 5 mg/ml powder for dispersion for infusion.

    Genmab A/S

    Malignant solid tumors: endometrial carcinoma (EC), urothelial carcinoma (UC), triple-negative breast cancer (TNBC), squamous cell carcinoma of the head and neck (SCCHN), or cervical cancer.

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many Phase II pipeline programs are in the directory?

7,238 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.